涩里番

subscribe

Strengthening Global Capacity Through a New Partnership with the PATH RNA Cooperative and support from the Gates Foundation

Montreal, QC, February 25, 2026 -聽涩里番鈥檚 DNA to RNA (D2R) Initiative - a $165M initiative funded by the Government of Canada through the Canada First Research Excellence Fund to turn genomic discoveries into RNA-based treatments - is expanding its global health impact.

Published: 25 Feb 2026

D2R X Norton Rose Fulbright | Protecting Your Ideas: A Guide for Innovators

鈥淚nnovation鈥 is everywhere these days鈥攂ut beyond the buzzword, what does it really mean for a young company, and how can you turn it into a concrete competitive advantage? This presentation demystifies intellectual property (IP) and shows why it matters far more than many founders think.

Published: 17 Feb 2026

D2R X NRC Biomanufacturing Collaboration Event

A half day showcase of聽D2R聽and the聽National Research Council鈥檚 shared biomanufacturing and bioengineering research priorities.

Published: 17 Feb 2026

涩里番 and Moderna Launch Breakthrough RNA Project Through D2R to Advance Made-in-Canada Innovation

Montreal, QC, February 5, 2026 鈥 涩里番 researchers, supported by the DNA to RNA (D2R) initiative and Moderna, are launching a pioneering research project that aims to further the fundamentals of ribonucleic acid (RNA) medicines by enhancing our understanding of the three-dimensional structure of full-length messenger RNA (mRNA).

Published: 5 Feb 2026

D2R invests over $1.2 million for Postdoctoral Scholars

Montreal, January 21, 2026聽鈥 The D2R | DNA to RNA Initiative at 涩里番 proudly announces the recipients of the inaugural Postdoctoral Scholar Awards. Alongside the Master鈥檚 and Doctoral Scholar awards, this funding program recognizes outstanding trainees working on diverse D2R-aligned research projects and brings outstanding postdoctoral researchers from across Canada and abroad to the D2R Initiative.

Published: 21 Jan 2026

Interview with Thomas Duchaine: a vaccine that fights COVID-19鈥 and cancer!

D2R's funded-researcher Thomas Duchaine recently sat down with聽Radio-Canada聽to discuss emerging research suggesting that RNA vaccines developed for COVID-19 may also enhance the effectiveness of certain cancer treatments.聽

Email address:
Published: 15 Dec 2025

Call for expressions of interest | Summer 2026 Internship

D2R is excited to announce this brand new opportunity for internships to聽Black undergraduate students in summer 2026 in partnership with聽COUHR.聽COUHR is a student-run non-profit organization partnering with research institutions across Canada to provide funded summer internships for underrepresented undergraduate students in fields such as neuroscience, biophysics, and genetics.

Published: 21 Nov 2025

EDI Workshop: Mental Health in Highly Performant Environments

Mental health in high-performing research environments is a shared responsibility and a growing challenge we must address together.

Every professor, student, research staff, and administrative staff can play a vital role in creating healthy, supportive, and inclusive research spaces. This includes standing by colleagues who disclose their disabilities and ensuring everyone can thrive.

Email address:
Published: 19 Nov 2025

Call for Summer 2026 Internship Supervisors

D2R and the聽Canadian Organization for Undergraduate Health Research聽launch a call for applications for a new internship opportunity

D2R is excited to announce this brand new opportunity to for internships Black undergraduate students in summer 2026.

Published: 10 Nov 2025

Hybrid Event | D2R Investor Series: Venture Capital Demystified - Investment Insights with In猫s Holzbaur

Every year, billions of dollars are invested by funding agencies in basic and translational research, yet the path from academic discovery to private investment necessary for the creation of new companies is rarely straightforward. In this seminar, you'll get an inside look at how investors work, what makes a research idea stand out to venture capitalists, and how they evaluate translational value of scientific opportunities.

Email address:
Published: 10 Nov 2025

D2R awards over $5.3 million in Foundational and Research in Motion funding programs

Montreal 鈥 November 6, 2025 | The鈥疍NA to RNA (D2R)鈥痠nitiative at 涩里番 is proud to announce the recipients of the second cycle of the Foundational and Research in Motion (RIM) funding programs.

Published: 6 Nov 2025

Genomic Medicine and Indigenous Health Award: Celebrating Excellence in Research

On October 23, at the 2025 Rendez-Vous G茅nome Qu茅bec in Montr茅al, Professor Treena Wasonti:io Delormier was announced as the recipient of the D2R Genomic Medicine and Indigenous Health Award.

Published: 28 Oct 2025

Video | Indigenous Engagement at D2R

D2R is deeply committed to fostering Indigenous leadership within the realms of genomic medicine, RNA therapeutics and health inequities. We believe research is strongest when it is guided by respect, collaboration and trust. Our approach both respects and relies on Indigenous governance structures and ethics to guide project development, data management, and dissemination of results, ensuring outcomes are beneficial and aligned with the priorities of Indigenous communities.

Published: 22 Oct 2025

EDI Internship Opportunity 鈥 Winter 2026

D2R and the Department of Equity, Ethics and Policy launch a call for applications for an EDI Internship Opportunity

Over the course of the Winter 2026 semester, work with Prof.

Published: 21 Oct 2025

Hybrid Event | D2R Investor Series Transform your science into a new Biotech company - Investment Insights with Medicxi

Every year, billions of dollars are invested by funding agencies in basic and translational research, yet the path from academic discovery to private investment necessary for the creation of new companies is rarely straightforward. In this seminar, you鈥檒l get an inside look at how investors work, what makes a research idea stand out to venture capitalists, and how they evaluate translational value of scientific opportunities.

Email address:
Published: 17 Oct 2025

Pages

Back to top